Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors

Archives of Pharmacal Research

Volumn 35, Issue 10, 2012, Pages 1723-1732

  Zhu, Yong ^a   Chen, Xin ^a   Wu, Zeng ^a   Zheng, Yixuan ^a   Chen, Yadong ^a   Tang, Weifang ^a   Lu, Tao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antiproliferative Activity; Design; Diaryl ether; HDAC inhibitors; Hydroxamic acid; Synthesis

Indexed keywords

3 [4 [3 (4 BROMOPHENYL)UREIDO]PHENOXY] N HYDROXYBENZAMIDE; 3 [4 [3 (4 CHLOROPHENYL)UREIDO]PHENOXY] N HYDROXYBENZAMIDE; 3 [4 [3 [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL]UREIDO]PHENOXY] N HYDROXYBENZAMIDE; 4 [4 [3 (3 METHOXYPHENYL)UREIDO]PHENOXY]BENZOIC ACID; 4 [4 [3 (4 BROMOPHENYL)UREIDO]PHENOXY]BENZOIC ACID; 4 [4 [3 (4 CHLOROPHENYL)UREIDO]PHENOXY]BENZOIC ACID; 4 [4 [3 (4 METHOXYPHENYL)UREIDO]PHENOXY]BENZOIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; N HYDROXY 3 [4 [3 (3 METHOXYPHENYL)UREIDO]PHENOXY]BENZAMIDE; N HYDROXY 3 [4 [3 (4 METHOXYPHENYL)UREIDO]PHENOXY]BENZAMIDE; N HYDROXY 4 [4 (3 PYRIDIN 2 YLUREIDO)PHENOXY]BENZAMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; SUBSTITUTION REACTION;

ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG DESIGN; ETHERS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872106590     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-1003-0     Document Type: Article

References (27)

1. Abreu, P. A., Dellamora-Ortiz, G., Leao-Ferreira, L. R., Gouveia, M., Braggio, E., Zalcberg, I., Santos, D. O., Bourguinhon, S., Cabral, L. M., Rodrigues, C. R., and Castro, H. C., DNA methylation: a promising target for the twenty-first century. Expert Opin. Ther. Targets, 12, 1035-1047 (2008).
2. Bolden, J. E., Peart, M. J., and Johnstone, R. W., Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 5, 769-784 (2006).
3. Butler, K. V. and Kozikowski, A. P., Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Des., 14, 505-528 (2008).
4. Chen, Y., Li, H., Tang, W., Zhu, C., Jiang, Y., Zou, J., Yu, Q., and You, Q., 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur. J. Med. Chem., 44, 2868-2876 (2009).
5. Consiglio, G. A., Failla, S., Finocchiaro, P., Giuffrida, C., and Recca, A., Easy synthetic approach to p-aminophenoxy derivatives bearing phosphonic or carboxylic ethyl ester groups. Phosphorus Sulfur Silicon Relat. Elem., 165, 7-16 (2000).
6. Conti, P., Tamborini, L., Pinto, A., Sola, L., Ettari, R., Mercurio, C., and De Micheli, C., Design and synthesis of novel isoxazole-based HDAC inhibitors. Eur. J. Med. Chem., 45, 4331-4338 (2010).
7. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., and van Kuilenburg, A. B., Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J., 370, 737-749 (2003).
8. Feng, R., Ma, H., Hassig, C. A., Payne, J. E., Smith, N. D., Mapara, M. Y., Hager, J. H., and Lentzsch, S., KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol. Cancer Ther., 7, 1494-1505 (2008).
9. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., and Pavletich, N. P., Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188-193 (1999).
10. Gediya, L. K., Chopra, P., Purushottamachar, P., Maheshwari, N., and Njar, V. C., A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J. Med. Chem., 48, 5047-5051 (2005).
11. Glaser, K. B., HDAC inhibitors: clinical update and mechanism- based potential. Biochem. Pharmacol., 74, 659-671 (2007).
12. Gregoretti, I. V., Lee, Y. M., and Goodson, H. V., Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol., 338, 17-31 (2004).
13. Grunstein, M., Histone acetylation in chromatin structure and transcription. Nature, 389, 349-352 (1997).
14. Marks, P. A., Discovery and development of SAHA as an anticancer agent. Oncogene, 26, 1351-1356 (2007).
15. Marks, P. A., Richon, V. M., and Rifkind, R. A., Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst., 92, 1210-1216 (2000).
16. Michan, S. and Sinclair, D., Sirtuins in mammals: insights into their biological function. Biochem. J., 404, 1-13 (2007).
17. Minucci, S. and Pelicci, P. G., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 6, 38-51 (2006).
18. Nielsen, T. K., Hildmann, C., Dickmanns, A., Schwienhorst, A., and Ficner, R., Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol., 354, 107-120 (2005).
19. Paris, M., Porcelloni, M., Binaschi, M., and Fattori, D., Histone deacetylase inhibitors: from bench to clinic. J. Med. Chem., 51, 1505-1529 (2008).
20. Schuetz, A., Min, J., Allali-Hassani, A., Schapira, M., Shuen, M., Loppnau, P., Mazitschek, R., Kwiatkowski, N. P., Lewis, T. A., Maglathin, R. L., McLean, T. H., Bochkarev, A., Plotnikov, A. N., Vedadi, M., and Arrowsmith, C. H., Human HDAC7 harbors a class IIa histone deacetylasespecific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem., 283, 11355-11363 (2008).
21. Seo, S. Y., Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug. Arch. Pharm. Res., 35, 197-200 (2012).
22. Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., Tang, J., Sang, B. C., Verner, E., Wynands, R., Leahy, E. M., Dougan, D. R., Snell, G., Navre, M., Knuth, M. W., Swanson, R. V., McRee, D. E., and Tari, L. W., Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure, 12, 1325-1334 (2004).
23. Sternson, S. M., Wong, J. C., Grozinger, C. M., and Schreiber, S. L., Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett., 3, 4239-4242 (2001).
24. Takai, N., Desmond, J. C., Kumagai, T., Gui, D., Said, J. W., Whittaker, S., Miyakawa, I., and Koeffler, H. P., Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res., 10, 1141- 1149 (2004).
25. Vassiliou, S., Mucha, A., Cuniasse, P., Georgiadis, D., Lucet- Levannier, K., Beau, F., Kannan, R., Murphy, G., Knauper, V., Rio, M. C., Basset, P., Yiotakis, A., and Dive, V., Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. J. Med. Chem., 42, 2610-2620 (1999).
26. Vickerstaffe, E., Warrington, B. H., Ladlow, M., and Ley, S. V., Fully automated multi-step solution phase synthesis using polymer supported reagents: preparation of histone deacetylase inhibitors. Org. Biomol. Chem., 1, 2419-2422 (2003).
27. Wolffe, A. P. and Guschin, D., Review: chromatin structural features and targets that regulate transcription. J. Struct. Biol., 129, 102-122 (2000).